Yongsheng Wang

1.5k total citations
54 papers, 927 citations indexed

About

Yongsheng Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yongsheng Wang has authored 54 papers receiving a total of 927 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Yongsheng Wang's work include CAR-T cell therapy research (11 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Treatments and Mutations (8 papers). Yongsheng Wang is often cited by papers focused on CAR-T cell therapy research (11 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Treatments and Mutations (8 papers). Yongsheng Wang collaborates with scholars based in China, United States and New Zealand. Yongsheng Wang's co-authors include Yuquan Wei, Diyuan Qin, Wei Wang, Fuchun Guo, Binglan Zhang, Zeming Mo, Hongfeng Gou, Yi Li, Wei Wei and Yi Li and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Yongsheng Wang

49 papers receiving 922 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yongsheng Wang China 20 545 310 282 196 119 54 927
Shengnan Yu China 10 503 0.9× 376 1.2× 177 0.6× 243 1.2× 156 1.3× 25 942
Huimin Tian China 18 448 0.8× 313 1.0× 360 1.3× 166 0.8× 143 1.2× 34 1.0k
Bruno A. Duso Italy 9 422 0.8× 354 1.1× 189 0.7× 186 0.9× 255 2.1× 21 879
Nomathamsanqa Resegofetse Maimela China 9 491 0.9× 298 1.0× 475 1.7× 143 0.7× 150 1.3× 12 901
Anliang Xia China 12 469 0.9× 455 1.5× 379 1.3× 106 0.5× 260 2.2× 18 960
Selva R. Murugesan United States 9 471 0.9× 297 1.0× 216 0.8× 229 1.2× 153 1.3× 13 970
Zhenya Hong China 18 689 1.3× 495 1.6× 315 1.1× 106 0.5× 130 1.1× 48 1.1k
Dongli Yue China 20 728 1.3× 533 1.7× 619 2.2× 192 1.0× 234 2.0× 41 1.4k

Countries citing papers authored by Yongsheng Wang

Since Specialization
Citations

This map shows the geographic impact of Yongsheng Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongsheng Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongsheng Wang more than expected).

Fields of papers citing papers by Yongsheng Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yongsheng Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongsheng Wang. The network helps show where Yongsheng Wang may publish in the future.

Co-authorship network of co-authors of Yongsheng Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Yongsheng Wang. A scholar is included among the top collaborators of Yongsheng Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongsheng Wang. Yongsheng Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Hang, Yu-Fei Wang, Yu-Fei Wang, et al.. (2025). Oxaliplatin accelerates immunogenic cell death by activating the cGAS/STING/TBK1/IRF5 pathway in gastric cancer. FEBS Journal. 292(14). 3814–3828.
2.
Yuan, Hongyan, et al.. (2025). CircCGNL1 Suppresses Nasopharyngeal Carcinoma Progression by Targeting IGF2BP3 and Inhibiting AKT/mTOR Signaling. Journal of Biochemical and Molecular Toxicology. 39(11). e70573–e70573.
3.
Wang, Yongsheng, Yan Huang, Yuanyuan Zhao, et al.. (2025). Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors. iScience. 28(5). 112497–112497. 2 indexed citations
4.
Ma, Yuxiang, Yuanyuan Zhao, Yongsheng Wang, et al.. (2025). Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study. Clinical Cancer Research. 31(21). 4438–4445. 3 indexed citations
5.
Zhao, Jian, et al.. (2025). The PI3K/Akt/mTOR Pathway: Immuno-Metabolic Orchestration in IR/MASH-Associated Hepatocellular Carcinoma. International Journal of Biological Sciences. 21(14). 6025–6041. 2 indexed citations
6.
Zhong, Liqiang, et al.. (2023). Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review). Oncology Letters. 26(1). 281–281. 33 indexed citations
7.
Shemesh, Colby S., Yongsheng Wang, Andrew An, et al.. (2023). Abstract CT266: Chinese race and origin have no clinically meaningful effect on tiragolumab and atezolizumab pharmacokinetics and safety in patients with advanced solid tumors. Cancer Research. 83(8_Supplement). CT266–CT266. 1 indexed citations
8.
Qin, Diyuan, et al.. (2023). Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies. Journal of Clinical Medicine. 12(19). 6124–6124. 30 indexed citations
9.
Ma, Qizhi, Pei Shu, Kexun Zhou, & Yongsheng Wang. (2023). Case Report: Termination of unplanned pregnancy led to rapid deterioration of non-small-cell lung cancer during osimertinib treatment. Frontiers in Oncology. 13. 1073938–1073938.
10.
Li, Jian, Jun Zhao, Baoshan Cao, et al.. (2022). A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 3089–3089. 25 indexed citations
11.
Gou, Zhongping, Xiandi Wang, Yongsheng Wang, et al.. (2021). Simultaneous quantification of cefuroxime and clindamycin in human lumbar anulus fibrosus, nucleus pulposus and serum via UPLC-MS/MS. Journal of Chromatography B. 1165. 122522–122522. 2 indexed citations
12.
13.
Jiang, Li, Fuchun Guo, Xiaoyu Li, et al.. (2019). Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC. Scientific Reports. 9(1). 3705–3705. 36 indexed citations
14.
Li, Junjie, Zhimin Shao, Binghe Xu, et al.. (2018). Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China. Medicine. 97(21). e10350–e10350. 13 indexed citations
15.
Yang, Jiadan, et al.. (2017). Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells. Immunology Letters. 190. 201–205. 5 indexed citations
16.
Li, Xuefeng, Sisi He, Xikun Zhou, et al.. (2016). Lyn Delivers Bacteria to Lysosomes for Eradication through TLR2-Initiated Autophagy Related Phagocytosis. PLoS Pathogens. 12(1). e1005363–e1005363. 46 indexed citations
17.
Wang, Wei, Diyuan Qin, Binglan Zhang, et al.. (2016). Establishing guidelines for CAR-T cells: challenges and considerations. Science China Life Sciences. 59(4). 333–339. 5 indexed citations
18.
19.
Yang, Tao, et al.. (2015). [Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in breast cancer with three-dimensional reconstruction technique].. PubMed. 53(4). 280–4. 3 indexed citations
20.
Niu, Zhimin, et al.. (2014). Psychosocial Response and Symptom Burden for Male Smokers with Lung Cancer. Asian Pacific Journal of Cancer Prevention. 15(1). 309–314. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shengnan Yu Breakdown of academic impact, for papers by Huimin Tian Breakdown of academic impact, for papers by Bruno A. Duso Breakdown of academic impact, for papers by Nomathamsanqa Resegofetse Maimela Breakdown of academic impact, for papers by Anliang Xia Breakdown of academic impact, for papers by Selva R. Murugesan Breakdown of academic impact, for papers by Zhenya Hong Breakdown of academic impact, for papers by Dongli Yue
Rankless by CCL
2026